# Table of contents

* [ğŸ’Š The Decentralized FDA DAO](README.md)
* [â˜  Problems We Seek To Address](1-introduction-and-challenges/README.md)
  * [ğŸ§® Bias Against Approving Effective Treatments](1-introduction-and-challenges/bias-against-approving-effective-treatments.md)
  * [ğŸ’° Clinical Research is Too Expensive](1-introduction-and-challenges/clinical-research-is-too-expensive.md)
  * [ğŸ­ Conflicts of Interest Industry-Controlled Research](1-introduction-and-challenges/conflicts-of-interest-industry-controlled-research.md)
  * [ğŸ© Excessive Patent Monopolies](1-introduction-and-challenges/excessive-patent-monopolies.md)
  * [â± Deaths Due to US Regulatory "Drug Lag"](1-introduction-and-challenges/deaths-due-to-us-regulatory-drug-lag.md)
  * [ğŸ¤’ Insufficient ROI to Discover Treatments for Rare Diseases](1-introduction-and-challenges/insufficient-roi-to-discover-treatments-for-rare-diseases.md)
  * [ğŸ™ˆ Negative Results are Never Published](1-introduction-and-challenges/negative-results-are-never-published.md)
  * [ğŸ—“ No Long-Term Outcome Data](1-introduction-and-challenges/no-long-term-outcome-data.md)
  * [ğŸ“ƒ No Incentive to Discover Benefits of Off-Patent Treatments](1-introduction-and-challenges/no-incentive-to-discover-benefits-of-off-patent-treatments.md)
  * [ğŸ¥« No Data on Unpatentable Molecules](1-introduction-and-challenges/no-data-on-unpatentable-molecules.md)
  * [ğŸ”® Pre-Determining Clinical Endpoints Requires Psychic Powers](1-introduction-and-challenges/pre-determining-clinical-endpoints-requires-psychic-powers.md)
  * [ğŸ¥¸ Trials Often Aren't Representative of Real Patients](1-introduction-and-challenges/trials-often-arent-representative-of-real-patients.md)
  * [â“ We Only Know The Effects of 0.000000002% of Potential Therapies](1-introduction-and-challenges/we-only-know-the-effects-of-0.000000002-of-potential-therapies.md)
  * [â˜  Slowed Growth in Life Expectancy](1-introduction-and-challenges/slowed-growth-in-life-expectancy.md)
* [ğŸª™ Futarchy-Based Efficacy Trials](6-tokenomics.md)
* [ğŸ“ˆ Supporting Evidence](supporting-evidence/README.md)
  * [ğŸ“ˆ Impact of Innovative Medicines on Life Expectancy](supporting-evidence/impact-of-innovative-medicines-on-life-expectancy.md)
  * [ğŸ“˜ Historical Evidence Supporting Real-Wold Efficacy Trials](supporting-evidence/historical-evidence-supporting-real-wold-efficacy-trials.md)
* [ğŸ¯ Goals](2-solution/README.md)
  * [ğŸ­ More Cures and Less Lifelong Attempts at Masking Symptoms](2-solution/more-cures-and-less-lifelong-attempts-at-masking-symptoms.md)
  * [ğŸ§ Greater Competitive Innovation and Fewer Monopolies](2-solution/greater-competitive-innovation-and-fewer-monopolies.md)
  * [ğŸ‘€ Lower Costs of Validated Observational Research for Efficacy](2-solution/lower-costs-of-validated-observational-research-for-efficacy.md)
  * [ğŸŒ Cost Savings from Decentralized Clinical Trials](2-solution/cost-savings-from-decentralized-clinical-trials.md)
* [ğŸ“– References](12-references.md)
* [ğŸ”¡ Definitions](definitions.md)
